Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From IASO Biotherapeutics
Plus deals involving Biocytogen/Radiance, Maruho/AOBiome, LGChem/Rhythm, IASO/Umoja, JW Therapeutics/2seventy and 13 other transactions.
Umoja’s technology is meant to enable development of CAR-Ts that could potentially overcome the challenges associated with autologous cell therapies, especially related to manufacturing.
Novartis pioneered CAR-Ts for leukemia and lymphoma, and inspired by pioneering physician Georg Schett, it also hopes to be first in the race to revolutionize autoimmune disease treatment with the therapies, and has unveiled the first clinical data for its candidate.
With the success of the partnership between J&J and partner Legend, more Chinese cell therapy developers are now looking to enter the US market. But for a complex product like a CAR-T therapy, the journey to the West is not short of challenges. Nasdaq-listed Gracell Bio wants to give it a shot based on quicker delivery and cost-effectiveness advantages.
- Gene Therapy, Cell Therapy
- Other Names / Subsidiaries
- Nanjing IASO Biotherapeutics
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.